


QUALITY WORKS.



# Meeting the Management 2017

## Structurally improving the financial profile

Michael Pontzen, CFO

**LANXESS**  
Energizing Chemistry

# Safe harbor statement


The information included in this presentation is being provided for informational purposes only and does not constitute an offer to sell, or a solicitation of an offer to purchase, securities of LANXESS AG. No public market exists for the securities of LANXESS AG in the United States.

This presentation contains certain forward-looking statements, including assumptions, opinions, expectations and views of the company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development or performance of LANXESS AG to differ materially from the estimations expressed or implied herein. LANXESS AG does not guarantee that the assumptions underlying such forward-looking statements are free from errors nor does it accept any responsibility for the future accuracy of the opinions expressed in this presentation or the actual occurrence of the forecast developments. No representation or warranty (expressed or implied) is made as to, and no reliance should be placed on, any information, estimates, targets and opinions, contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein, and accordingly, no representative of LANXESS AG or any of its affiliated companies or any of such person's officers, directors or employees accept any liability whatsoever arising directly or indirectly from the use of this document.

# Transformation of the financial profile


- Recap from a financial perspective
- Financial improvements to come
- Deconsolidation of ARLANXEO

# 2015 starting point: Dedicated value maximizing strategy for each business unit



# Restructuring and change of strategy yields first positive results

## LANXESS transformation starts to become visible



Substantial room for improvement left

## Key 2016 points

- Phase 1 & 2 cost improvements become visible
- All BUs with improved organic return profile
- Growth is picking up




# Transformation of the financial profile

- Recap from a financial perspective
- **Financial improvements to come**
- Deconsolidation of ARLANXEO

# Transformation of the financial profile

- Recap from a financial perspective
- Financial improvements to come
  - Attractive organic investments
  - Integration of Chemtura
  - Cash conversion improvement
- Deconsolidation of ARLANXEO

# Growth capex in New LANXESS were value enhancing



\* Sum of business units



# Value creating investments are going to continue

**Planned  
growth  
capex  
2016 – 2020**

**Factor for  
success**

## Advanced Intermediates



**~€150 m**

Focus on brownfield investments to strengthen “Verbund” platform and reinforce cost advantage

## Specialty Additives



**€50 – 100 m**

Investing in technology and process upgrades and product development


## Performance Chemicals



**€50 – 100 m**

Investment in application technology and customer solutions

## Engineering Materials




**€50 – 100 m**

Expansion of low capital intense downstream assets to further improve product mix

**Total capex of ~€400 m with expected  $\emptyset$  ROCE ~20%**

# BU All: Brownfield expansion of existing manufacturing platform with highly attractive returns

## Sensible debottleneckings to serve market growth



**Total capex ~€100 m with Ø ROCE ~20%**

## Value investments


- Focus on brownfield investments
- Focus on continued technology upgrades and debottlenecking
- Further dilution of fixed costs
- Further improving excellent cost position

**Support volume growth**

Construction Ramp-up / production

# BU HPM: Low capex intensity of downstream investments will further support the “balanced capacity model”

## Expanding global compounding network inline with demand




**Total capex €50 – 100 m with Ø ROCE ~20%**

Construction Ramp-up / production

## Value investments

### Capacity split

Illustrative




Mix improvement

**More stable and attractive returns**

# Actual utilization rates offer additional headroom

## Increased profitability at stable utilization rates



- Rising share of EBITDA pre from New LANXESS businesses fueled margin improvement
- No indication of peak utilization rates
- Capex of the past allows to serve expected volume growth
- Growth capex adds to margin improvement




Potential for further increase in utilization rates and upside in financial performance

# Transformation of the financial profile

- Recap from a financial perspective
- Financial improvements to come
  - Attractive organic investments
  - Integration of Chemtura
  - Cash conversion improvement
- Deconsolidation of ARLANXEO

# Bottom-up analysis confirm former synergy targets

## Implementation of synergies on track

[€m]	2017	2018	2019	2020	Total	
<b>Synergies</b>	~25	~25	~35	~15	~100	
<b>Expense (one-time costs)*</b>	~50	~50	~20	~20	~140	
<b>Cash out*</b>	~30	~40	~40	~30	~140	
<b>Capex</b>	~30	~10	~10		~50	

## Previous assumptions


- **Synergies confirmed**
  - €100 m of “hard” costs
  - Top line synergies not included
- ~€50 m capex for asset improvements
- ~€140 m one time costs
- ~€80 m transaction related cash outs, mostly in 2017

\* excluding ~€80 m transaction related charges

# Chemtura Synergies: Contribution from all cost categories

## Synergies in all functions

Administration  
~30%



Production &  
procurement  
~50%

Marketing & sales  
~20%



# Synergy example I: Integration of admin organization

## Corporate center

### Facts

- Chemtura had a corporate center of a listed company



### Implementation


- 34 projects have been identified; e.g.:
  - Board of management, governance functions
  - Fees (e.g. audit, rating, listing)

~€10-15 m synergies in 2017-2018

## General administration

### Facts

- E.g. two US administration organizations



### Implementation

- 60 projects have been identified; e.g.:
  - Eliminate double functions & integrate IT systems, optimize cost of insurance coverage
  - Combine office locations in close regional proximity

~€10-15 m synergies 2017-2019; ~€5-10 m capex



# Synergy example II: Integration of procurement and logistics activities

## Direct material sourcing

### Facts

- “New LANXESS” raw material purchase volume amounts to ~€2.5 bn

### Rationale

- Use purchasing power of enlarged organization and harmonize contract prices

### Implementation

- 36 projects have been identified:
  - Harmonizing contracts with joint suppliers
  - Bundling of volumes and use of price arbitrage
  - Insourcing of e.g. maleic anhydride, bromine etc.

~€10-15 m synergies in 2018/2019

## Logistics

### Facts

- Both companies operate ~200 warehouses globally

### Rationale

- Chemtura had outsourced most logistic operations to third parties thereby losing critical know-how

### Implementation


- 38 projects have been identified
  - Cutting sea and land based transport costs by using LANXESS' freight rates
  - Bundling of warehouses and optimizing set-up

~€5-10 m synergies 2017-2019; ~€5-10 m capex

# Transformation of the financial profile

- Recap from a financial perspective
- Financial improvements to come
  - Attractive organic investments
  - Integration of Chemtura
  - Cash conversion improvement
- Deconsolidation of ARLANXEO

# LANXESS free cash flow and cash conversion rate to improve



\* Calculated as  $(\text{EBITDA pre} - \text{capex}) / \text{EBITDA pre}$

# LANXESS financial profile will transform

**New LANXESS will be fundamentally changed**


**Regional platform**



**Industrial platform**



**Market positions**



**EBITDA pre margin  
14–18%  
(through the cycle)**

**Cash conversion\* >60%**

**Lower volatility of  
earnings**

\* Calculated as (EBITDA pre – capex) / EBITDA pre


# Transformation of the financial profile

- Recap from a financial perspective
- Financial improvements to come
- **Deconsolidation of ARLANXEO**

# ARLANXEO with marginal contribution to EPS – New LANXESS tax rate reduced after deconsolidation


## Minor ARLANXEO contribution to EPS

H1 2017 LTM



High ARLANXEO D&A after heavy investment cycle

## Tax rate of New LANXESS will be at 30-35%



High ARLANXEO tax rate due to unfavorable regional distribution of earnings

# ARLANXEO deconsolidation will lead to a substantial reduction of currency risk

## Substantially reduced FX sensitivity


- Chemtura consolidated since 21 April 2017
- ARLANXEO reported as disc. operations from 01 April 2018

**1ct change in the USD/EUR rate impacts EBITDA  
by ~€7 m before hedging  
(was ~€9 m before)**



# Volatility of working capital will be significantly reduced after deconsolidation of ARLANXEO

## ARLANXEO significantly impacted free cash flow in the past



- Butadiene, one of the main raw materials for ARLANXEO, with strong volatility
- Butadiene volatility main driver for working capital changes in the past

**Volatility of working capital will be significantly reduced**



# LANXESS transformation will lead to an improved financial profile

Strategy implementation with deep financial mindset

Integration benefit and financially highly attractive organic growth projects drive profitability

Continued focus on increasing free cash flow generation, paired with less volatility

LANXESS is committed to a solid investment grade rating





**... to be continued.**